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1 
BIOCOMPATIBLE NANO RARE EARTH 
OXIDE UPCONVERTERS FOR IMAGING 
AND THERAPEUTICS 
2 
Metal fluorides, oxysulfides and phosphates are the matri-
ces widely used to study the up conversion process and only 
a few reports are available with oxides. However, in order to 
have biocompatibility, a silica layer has been often coated on 
the surface of up conversion phosphors. Among the rare earth 
oxides, cerium oxide nanoparticles (CNPs) are shown to be 
biocompatible and exhibit regenerative antioxidant proper-
ties. 
This application claims the benefit of priority to U.S. Pro-
visional Application No. 61/081,903 filed on Jul. 18, 2008 
and was funded in part by National Science Foundation 
Nanoscale Interdisciplinary Research Teams (NSF NIRT) 
(0708172 CBET) and National Institutes of Health (NIH) 
ROI (1R01AG031529-01). 10 
Earlier studies by co-inventors indicate that cerium oxide 
nanoparticles offer carbonic anhydrase inhibition, protection 
of primary cells from the detrimental effects of radiation 
therapy, prevention ofretinal degeneration induced by intra-
cellular peroxides, and neuroprotection to spinal cord neu-
rons and have radical scavenging properties. By tailoring the 
FIELD OF THE INVENTION 
This invention relates to nanoparticles and, in particular, to 
methods and systems for up-converter tagged nanoparticles 
and up conversion nano cerias for site selective drug delivery 
and treatment of diseases. 
BACKGROUND AND PRIOR ART 
Understanding the complex spatio-temporal interplay of 
nanomaterials used as therapeutics at the cellular to the 
molecular level is required for designing nanoparticle based 
therapeutics and biomarkers for many diseases. To study 
these interactions, fluorescent labeling is commonly used for 
both in vivo cellular imaging and in vitro assay detection. 
Conventional fluorescence imaging involves single photon 
excitation of higher energy to emit lower energy light, a 
process known as down conversion. Organic dyes, metal and 
semiconductor nanoparticles are widely used as fluorophores 
to follow ligands into the cells and within tissue in animals as 
described in Michalet X, Pinaud F, Bentolila L, Tsay J, Doose 
S, Li J, Sundaresan G, Wu A, Gambhir S, Weiss S. Quantum 
Dots for Live Cells, in Vivo Imaging, and Diagnostics. Sci-
ence 2005; 307, pp. 538-544. The fluorophores suffer from 
auto-fluorescence from biological tissues, photobleaching, 
low signal-to-noise ratio, potential damage to DNA and cell 
death as described in Green M, Howman E. Semiconductor 
quantum dots and free radical induced DNA nicking. Chem 
Commun 2005, pp. 121-123 and in Riegler J, Nann T. Appli-
cation of luminescent nanocrystals as labels for biological 
molecules. Anal Bioanal Chem 2004, 379, pp. 913-919. 
Up conversion phosphors (UCPs) capable of converting 
near infrared (NIR) radiation into shorter wavelengths 
through a multi-photon process, offers an alternative with 
minimal photo damage and auto-fluorescence due to the non-
invasive nature oflight as described inAuzel F. Upconversion 
and Anti-Stokes Processes with f and d Ions in Solids. Chem 
Rev 2004, pp. 139-173. Since up conversion occurs within the 
host crystal and is therefore less affected by the chemical and 
biological environments, and allows synthesis of materials 
without the loss of surface chemical reactivity. 
15 surface potential or conjugating with targeting agents, spe-
cific uptake of cerium oxide nanoparticles in cells can be 
achieved. Although enhanced cellular uptake has been opti-
mized based on surface characteristics, the mechanism of 
interaction, absorption and metabolism of these nanomateri-
20 als under in vivo condition is poorly understood. 
The interaction of cerium oxide nanoparticles with cells 
and tissues needs to be well established for biomedical appli-
cations. Through real time imaging of cell-nanoparticle inter-
actions it is possible to better understand the complex pro-
25 cesses and conditions that facilitate or inhibit the uptake and 
release of materials into the cytosol or other intracellular 
targets. But, cerium oxide nanoparticles show weak emission 
characteristics in visible region, inhibiting the direct use of 
these materials for imaging purposes. One of the approaches 
30 to enhance the emission of cerium oxide nanoparticles is by 
doping with europium which has strong emission in the vis-
ible region. But, combining the non-toxic, biocompatible 
properties of cerium oxide nanoparticles with up conversion 
dopants would be a novel approach to optimize the emission 
35 properties. However, it is important to assess the interaction 
between the nanoparticles and cells since the biocompatibil-
ity and cellular uptake properties determine the therapeutic 
and imaging applications. 
The present invention focuses on the formulation of co-
40 doped cerium oxide nanoparticles with Yb3 + sensitizer and 
mainly Er3 + as an emitter. These co-doped, annealed cerium 
oxide nanoparticles will hereafter be referred to as up con-
version nano ceria (UNC). In order to demonstrate the emis-
sion wavelength tunability, the emitter ion was changed to 
45 Ho3 + or Tm3 +. The physical and optical properties of up 
conversion nano ceria and characteristics of these novel mate-
rials in various cells (A549, WI-38, HUVEC) were investi-
gated by the co-inventors. In order to assess the antioxidant 
properties, catalase mimetic activity to catalyze the decom-
50 position of hydrogen peroxide into water and oxygen was 
studied. The influence of nanoparticle interaction on the cell 
viability ofnormal lung fibroblasts (CCL-135) and cancerous 
cells (CRL-5803) were analyzed. 
All these favorable properties indicate that there is a real 
potential for the development of up conversion phosphors in 55 
the analysis of biological samples, especially for fluorescent 
imaging in vivo. Up conversion phosphors contain a sensi-
tizer ion which absorbs the near infrared photons and trans-
fers the absorbed energy sequentially to excite an emitter ion 
into a state which then emits in the visible. Lanthanide ions 60 
are particularly suitable candidates for up conversion pro-
cesses because of their energy level structure providing many 
intermediate levels with favorable spacings and long-lived 
excited states. Yb3 + ions have been widely used as sensitizer 
SUMMARY OF THE INVENTION 
A primary objective of the invention is to provide methods, 
apparatus and systems for doping cerium oxide and other 
therapeutically valuable nanoparticles with rare earth ions 
either singly or in combinations so that infrared light is 
absorbed and visible light is emitted through the process of up 
convers10n. 
A secondary objective of the invention is to provide a novel 
type of therapeutic nanoparticle with rare earth doping to 
provide for up conversion emission for tracking and evaluat-
ing the functionality of the nanoparticles and further elucida-
tion of ROS scavenging mechanism. 
as Yb3 + ions exhibit a relatively large absorption cross section 65 
in the near infrared region allowing excitation with laser 
diodes. 
US 9,127,202 Bl 
3 
A third objective of the invention is to provide methods, 
apparatus and systems for using up converting rare earth 
nanoparticles to locate and estimate their presence in cells for 
finding, tracking and evaluating the therapeutic functionality 
of nanoparticles and other therapeutic agents in biological 
systems. 
4 
FIG. Sa shows up conversion nano ceria absorbed by 
human cells of A549 in a culture under ambient light. 
FIG. Sb shows up conversion nano ceria absorbed by 
human cells of A549 in a culture under ambient light plus 
infrared laser excitation. 
FIG. Sc shows up conversion nano ceria absorbed by 
human cells of HUVEC in a culture under ambient light. 
FIG. Sd shows up conversion nano ceria absorbed by 
human cells ofHUVEC in a culture under ambient light plus 
10 infrared laser excitation. 
A first embodiment provides a method of doping a cerium 
oxide nanoparticle with one or more dopants to form co-
doped up conversion nanoparticle ceria, at least one of the 
dopants absorbing infrared light and emitting visible light 
through the process of up conversion. The dopants are 
obtained from one or more nitrates selected from the group 
including ofYb, Er, Ho, Tm and Pr, such as co-doping Yb with 
one or more nitrates from the group consisting of Er, Ho, Tm 
and Pr, doping a cerium oxide nanoparticle with one ofYb3+ 
and Er3+, or adding one of Er+, Ho3+ and Tm3+ to the Ce02 
nanoparticle. In an embodiment the up conversion nanopar-
ticle ceria are Er, Yb doped Ce02 particles. Applications 
include using the up converting nano ceria nanoparticles to 
locate cells using the up converting nano ceria nanoparticles 20 
for finding, tracking and evaluating therapeutic agents in 
biological systems. 
FIG. Se shows up conversion nano ceria absorbed by 
human cells ofWI-38 in a culture under ambient light. 
FIG. Sf shows up conversion nano ceria absorbed by 
human cells ofWI-38 in a culture under ambient light plus 
15 infrared laser excitation 
FIG. 6a is a graph showing the conversion of hydrogen 
peroxide to oxygen was followed by measuring decreases in 
hydrogen peroxide levels via ultraviolet absorption showing 
catalase mimetic activity. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Beyond Yb oxides, the embodiments also contemplate as 
up conversion sensitizer dopants metal oxides selected from 
the group including but not limited to La, Nd, Gd and Eu rare 25 
earth metal oxides. 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
As another embodiment, a cerium oxide nanoparticle is 
co-doped with a rare earth oxide selected from the group 
consisting of La, Nd, Gd and Eu with Yb sensitizer and Er as 
an emitter. 
The cerium oxide nanoparticle can be co-doped with an 
up-converting material to form an up conversion nano ceria 
that absorbs infrared light and emits visible light through the 
process of up conversion including emitting one of a red, a 
green and a blue light. 
Further objects and advantages of this invention will be 
apparent from the following detailed description of preferred 
embodiments which are illustrated schematically in the 
accompanying drawings. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a block diagram of the experiment used to deter-
mine the emission spectra of the samples. 
FIG. 2a is a HRTEM micrograph showing up conversion 
nano cerias with a size in the range between approximately 20 
to approximately 40 nm. The inset shows the selected area 
electron diffraction pattern that shows the presence of fluorite 
structure. 
FIG. 2b is a HRTEM micrograph showing up conversion 
nano cerias with a size in the range of approximately 20 nm. 
FIG. 2c shows an EDAX spectrum of the nano particle 
showing the presence of Ce, Yb, Er and 0 along with C and 
Cu. 
FIG. 2d shows an x-ray diffraction pattern that indicates the 
retention of fluorite structure of ceria. 
FIG. 3a shows the optical absorption spectrum of up con-. . 
vers10n nano cena. 
FIG. 3b shows the measured emission spectra of samples. 
FIG. 3c shows the measured emission decay dynamics of 
the red light emitted from the up conversion nano ceria. 
FIG. 4a shows up conversion nano cerias are not toxic in 
cell culture models of A549. 
FIG. 4b shows up conversion nano cerias are not toxic in 
cell culture models ofWI-38. 
FIG. 4c shows up conversion nano cerias are not toxic in 
cell culture models of HUVEC. 
30 Prior up-conversion patents include U.S. Pat. No. 5,089, 
860 issued to Deppe et al, on Feb. 18, 1992, U.S. Pat. Nos. 
6,327,074 and 6,501,590 issued to Bass et al. respectively on 
Dec. 4, 2001 and Dec. 31, 2002, U.S. Pat. No. 6,654,161 
issued to Bass et al. on Nov. 25, 2003, U.S. Pat. No. 6,844,387 
35 issuedtoBassetal.onJan.18,2005, U.S. Pat.No. 7,075,707 
issued to Rapaport et al. on Jul. 11, 2006 and U.S. Pat. No. 
7 ,4 71,306 issued on Dec. 30, 2008 having a common inventor 
and assigned to the same assignee as the subject invention are 
40 
incorporated herein by reference hereto. 
U.S. patent application Ser. No. 12/365,971 filed on Feb. 5, 
2008; Ser. Nos. 12/124,620 and 12/124,234 filed on May 21, 
2008, Ser. No. 12/349,712 filed on Jan. 7, 2009, Ser. No. 
12/365,971 filed on Feb. 5, 2009 and61/180,475 filed on May 
22, 2009 each having a common inventor and which are 
45 assigned to the same assignee as the subject invention, are 
also incorporated herein by reference hereto. 
The present invention relates to the synthesis of rare earth 
co-doped cerium oxide nanoparticles having strong NIR-to-
visible up conversion fluorescence. The tunability of emis-
50 sion wavelength was studied with respect to co-dopant chem-
istry on excitation with the wavelength of 975 nm. Cellular 
uptake of nanoparticles in A549, WI-38 and HUVEC cells 
was followed with NIR excitation and cytotoxicity of the 
particles were assessed by using MTT and LDH assay. Anti-
55 oxidant catalase mimetic activity of nanoparticles was fol-
lowed by the decomposition of hydrogen peroxide. Cell 
viability of normal lung fibroblasts and lung cancer cells with 
nanoparticle was investigated to ascertain the interaction of 
nanoparticle with normal and cancerous cells. The results 
60 from this study revealed that the biocompatible, co-doped 
cerium oxide nanoparticles exhibited strong up conversion 
properties which can be utilized for real time tracking of 
nanoparticles such as in cellular uptake as well as in biocata-
lytic activity, demonstrating the potential applications in can-
65 cer therapy. 
The present invention focuses on the formulation of co-
doped cerium oxide nanoparticles with Yb3+ sensitizer and 
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mainly Er3 + as an emitter. These co-doped, annealed cerium 
oxide nanoparticles will hereafter be referred to as up con-
version nano ceria (UNC). In order to demonstrate the emis-
sion wavelength tunability, the emitter chemistry was 
changed to Ho3 + or Tm3 +. The physical and optical properties 
of up conversion nano ceria and characteristics of these novel 
materials in various cells including A549, WI-38, and 
HUVEC were investigated by the co-inventors. In order to 
assess the antioxidant properties, catalase mimetic activity to 
catalyze the decomposition of hydrogen peroxide into water 10 
and oxygen was studied. The influence of nanoparticle inter-
action on the cell viability of normal lung fibroblasts (CCL-
135) and cancerous cells (CRL-5803) were analyzed. 
Experimental Data: 
Analytical grade nitrates of Ce, Yb, Er, Ho and Tm from 15 
Sigma-Aldrich Chemical Inc. were used for synthesis of up 
conversion nanophosphors. Ammonia solution (IN Alfa 
Aesar) was added to aqueous nitrate solutions of Ce3 + (0.1 
M), Yb3 + (20%) and Er3 + (2%) to maintain the pH above 10. 
The resultant precipitate was washed, armealed at 900° C. and 20 
filtered through 100 nm membrane filter, referred as up con-
version nano ceria. A similar procedure was used to synthe-
size Ce02 :20% Yb, 2% Ho and Ce02 :20Yb %, 0.5% Tm. 
The powders were characterized by X-ray diffraction 
(Rigaku) and high resolution transmission electron micros- 25 
copy (Tecnai F30) to evaluate the structure and size. The 
optical absorption spectrum was recorded with Cary 500 
Spectrophotometer. A diode laser emitting at 975 nm was 
used was used for the luminescence and time decay studies. 
Only up conversion nano cerias were used for imaging and 30 
therapeutic property assessment. 
A549, WI-38, CRL-5803, and CCL-135 were obtained 
fromAmerican Type Culture Collection (Manassa, Va., USA) 
and Human Umbilical Vascular Endothelial Cells (HUVEC) 
cells were obtained from Lonza Walkersville, Inc. (Walkers- 35 
ville, Md., USA).A549, CRL-5803, andCCL-135 cells were 
cultured in Dulbecco's modification of Eagle's medium 
(DMEM) (Mediatech, Inc, Manassa, Va., USA) supple-
mented with 10% fetal bovine serum (FBS) (Equi-tech Bio, 
Kerrville, Tex., USA) and 100 IU mL- 1 penicillin (Mediat- 40 
ech, Inc, Manassa, Va., USA). WI-38 cells were cultured in 
Eagle's Minimum Essential Medium (EMEM) supplemented 
with 10% FBS and 100 IU mL- 1 penicillin. HUVEC cells 
were cultured in Endothelial Cell Medium (ECM) (Science-
Cell, San Diego, Calif., USA) supplemented with 5% FBS 45 
and 100 IU mL- 1 penicillin. All cultures were maintained at 
37° C. in a humidified incubator under a 5% atmosphere of 
C02 . 
Cells were cultured in 96-well culture dishes using appro-
priate media conditions and treated with up conversion nano 50 
cerias in varying concentrations; 0, 50, 250, 500, 750, 1000 
µMand incubated for 24 hat 37° C. MTT dye (3-(4,5 dim-
ethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Am-
resco, Solon, Ohio, USA) was added to a final 1.2 mM con-
centration and cells were incubated another 4 hours at 37° C. 55 
To solubulize the dye, cells were lysed (10% SDS, 0.01 M 
HCl) and incubated overnight at 37° C. Absorbance was 
measured at 570 nm using a SpectraMax 190 spectrophom-
eter (Molecular Devices, Surmyvale, Calif., USA). Cell pro-
liferation was determined by dividing the absorbance of 60 
treated samples to untreated controls and reported as a per-
centage. Lactate dehydrogenase (LDH) release was mea-
sured in presence of up conversion nano ceria using Cytotox-
icity Detection KirLus (LDH) (Roche Diagnostics, 
Germany). In short, supernatants from each well was col- 65 
lected and spun to remove cell cellular debris. Freshly pre-
pared reaction mixture was added, incubated for 15 min at RT 
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protected from light. Stop solution was added and absorbance 
was measured at 490 nm. LDH release was determined as 
percentage of untreated control samples. 
All samples for microscopy were prepared as follows. 
Cells were grown to approximately 60-70% confluence. After 
24 hour treatment with various up conversion nano ceria 
concentrations, cells were washed 2 times in appropriate 
saline (A549 and WI-38, Dulbeccos's Phosphate Buffered 
Saline, (Mediatech, Inc, Manassa, Va., USA), HUVEC, 
Hepes Buffered Saline without Phenol Red, (Lonza Walkers-
ville, Inc., Walkersville, Md., USA), trypsinized and trans-
ferred to glass coverslips. After a further 24 hour growth, cells 
were washed 2 times in appropriate saline, fixed in cold (20° 
C.) methanol for 10 min at RT then washed 2 times with 
sterile water. 
All spectrophotometric data was collected using a 40 µL 
quartz cuvette with a 1 cm path length in a Hewlett-Packard 
diode array UV-visible 8453 spectrophotometer. Reactions 
were carried out in assay buffer containing 50 mM Tris, pH 
7.5 and 1 mM diethylenetriaminepentacetic acid (DTPA) to 
chelate any possible adventitious metal. Hydrogen peroxide 
(Acros Organics) was added to start the reaction and samples 
were analyzed for a total of 600 seconds with a cycle time 
(time point) of 0.5 seconds at a wavelength of 240 nm. Up 
conversion nano ceria preparations were reconstituted in H20 
to initial concentration of 10 µM and ultrasonicated for 45 
min before use. 
To evaluate the size of up conversion nano cerias, high 
resolution transmission electron microscopic (HRTEM) 
studies were carried out. In the as prepared condition size of 
the nanoparticle was found to be in the range of7-10 nm. In 
the experiment, the size of the nanoparticle was between 
approximately 7 and approximately 10 nm while the mean 
crystallite size was calculated to be approximately 8.4 nm. 
Lattice parameter was found to be approximately 0.5423 nm 
in the as prepared condition and decreased to 0.5412 nm upon 
annealing. Cerium can exist in either +3 or +4 oxidation 
states. In the nano scale the concentration ofCe3 increases. As 
a result of higher ionic radii of Ce3 + (0.1143 nm) than Ce4 + 
(0.97 nm), the lattice parameter is larger than that ofbulk ceria 
(0.541 nm). Further, trivalent Yb and Er dopant ions have 
higher ionic radii (0.0985 nm and 0.1004 nm, respectively) 
than that of Ce4 +. As a result prepared nanoparticles have 
higher lattice parameter than that of bulk ceria. On armealing 
Ce3 + concentration decreases leading to a reduction in the 
lattice parameter. 
Since the nanoparticle was in the form of a powder, a strip 
of dual sided transparent tape was placed on a glass slide and 
the particles were sprinkled on the exposed sticky side of the 
tape. This resulted in a sample that could be placed in the 
spectrophotometer so that its absorption spectrum could be 
measured. The absolute value of the absorption strength was 
not critical to the project but the absorption spectrum was and 
such samples enabled absorption spectra measurements. The 
emission spectra of co-doped cerium oxide nanoparticles 
were measured using the apparatus shown in FIG. 1. This 
procedure had been developed in prior research (A. Rapaport, 
J. Milliez, M. Bass, A. Cassanho, H. Jenssen, J. of Display 
Technology 2006, 2, 68). 
A diode laser emitting at 97 5 nm excited samples placed in 
the integrating sphere as indicated. The particles being stud-
ied were confined in a small cavity at the center of a clear 
cabochon. In FIG. 1, the metal mirror indicated in the block 
diagram was removed so that the green emission from a 
sample could be photographed. An integrating sphere and 
Instrument Systems CAS 140B spectrometer enabled collect-
ing the emitted light and measurement of its spectrum. For 
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decay studies, a Spectra Physics MOPO laser generating 
pulses at approximately 975 nm of about 4 nsec duration at 
approximately 10 Hz pulse repetition frequency was used to 
excite the samples and enable measurement of the emission 
decay dynamics. The emitted light was directed through a 97 5 
nm blocking filter to a fast detector (Hamamatsu PMT 
H6780-20 with sub 1 nsec rise time) which was connected to 
a Tektronix 2440 oscilloscope (FIG. 2b ). The recorded decays 
were stored digitally and later analyzed with Origin software. 
8 
540 nm 4 S312--;.
4 I512 transition) due to Er3+. On co-doping 
with Ho3+ green emission appears as a result of 5 F 4 , 
5 S2 --;.
5 I8 
transition along with weak red light. Tm3 + co-doping results 
in weak blue emission (1G4 --;.
3 H6) due to reduced probability 
for multi photon transition; inset demonstrates the red emis-
sion from up converter nano ceria observed from an optical 
microscope under NIR excitation. Scale bar in the inset cor-
responds to 10 µm. FIG. 3c is a graph showing the measured 
emission decay dynamics of the red light emitted from up 
Equipment was set up for the experiment to detect the 
nanoparticles when viewed through the microscope. First up 
conversion nano cerias were placed on a microscope slide 
and, when excited by the 975 nm light from the diode laser, 
were seen to emit red light. Then the particles were placed in 
10 converter nano ceria. The solid line is an exponential decay fit 
with decay time of 10.6 µsec. On near infra red excitation 
(975 nm), emission wavelengths can be tuned from red, green 
or blue on varying the co-dopant chemistry from Er3 +, Ho3+ 
a cell culture and when exposed to 975 nm light could be 15 
detected and distinguished easily from other black spots in 
the field of view. The doped nanoparticles were those black 
spots that emitted red light when exposed to the diode laser 
light as shown in FIGS. Sa through Sf The images were 
captured by a CCD camera when the excitation is on and the 20 
emitting nanoparticles were seen as the red emitting items in 
the displayed image. To protect an experimenter from inad-
vertently being exposed to 975 nm laser light, the beam path 
was placed in an enclosure and a filter that blocked 975 nm 
light was placed in the microscope optics before any light 25 
could reach either the eyepieces or the CCD camera. 
FIG. 2 shows the characterization of up conversion nano 
cerias. FIG. 2a is a HRTEM micro graphs showing up conver-
sion nano cerias with a size range of approximately 20 to 
approximately 40 nm. The inset in FIG. 2a shows the SAED 30 
pattern from A to D corresponding to (111), (200), (220) and 
(311) planes. The HRTEM in FIG. 2b shows up conversion 
nano cerias having the primary particle size of approximately 
or Tm3+, respectively. 
From this data it is clear that the Er3+ ions in cerium oxide 
nanoparticles emit principally in the red emission between 
approximately 640 and approximately 700 nm while Ho3+ 
co-doping results in the green emission between approxi-
mately 530 and approximately 570 nm. Samples with Tm3+ 
as the co-dopant were expected to emit blue light but the 
emission, if any, was too weak due to lower probability of 
multiphoton process. Up conversion nano ceria powders with 
Yb3+ and Er3+ co-dopants when excited by approximately 
975 nm light from the diode laser could be easily seen to emit 
red light. 
In earlier studies using fluoride hosts, the decay dynamics 
indicate a fluorescent lifetime ofabout 3 ms compared to 10.6 
µs for up conversion nano ceria. A very short emission time 
observed in the present work indicates the presence of sig-
nificant fluorescence quenching. Since oxide matrices have 
higher phonon energy than the fluorides this strong quench-
ing is not surprising. In spite of quenching, the up conversion 
emission intensity is sufficient to utilize the water dispersible 
up conversion nano cerias as potential biomarkers. Thus, the 
emission color can be tuned from red, green or blue by vary-
ing the co-dopant from Er3 +, Ho3+ and Tm3 +, respectively. 
Recently several studies have shown that cerium oxide 
nanoparticles have potential for use as a biological antioxi-
dant but opinion on toxicity of cerium oxide nanoparticles in 
20 nm. The interplanar distance corresponds to (111) plane of 
flurite structured ceria. The EDAX spectrum of the nanopar- 35 
ticle in FIG. 2c shows the presence of Ce, Yb, Er and 0 along 
with C and Cu which comes from TEM grid. In FIG. 2d, the 
X-ray diffraction pattern indicates the retention of fluorite 
structure of ceria even upon armealing (JCPDS card No. 
81-0792). 
On annealing, up conversion nano cerias have a primary 
particle size of about 20 nm along with a few particles in the 
size range of 40 nm, as a result interfusion to form larger 
particles due to annealing as shown in FIGS. 2a and 2b. 
Selected area electron diffraction (SAED) pattern shows the 45 
presence of fluorite structure as shown in the inset in FIG. 2a. 
Although the core particles still retained the nano size, the 
presence of few larger agglomerates is evident after filtration. 
From Energy dispersive analysis of X-rays as shown in FIG. 
40 cell culture models differs. As a result, although up conver-
sion cerias have visible emission, the important step towards 
the biomedical application is to assess the toxicity in a wide 
range of concentrations. For the studies resulting in the 
2c and X-ray diffraction shown in FIG. 2d, it can be con- 50 
eluded that Yb3+ and Er3+ were doped into the matrix of 
cerium oxide nanoparticles and hence no modification in 
diffraction pattern. 
Previous studies of up conversion showed that fluoride 
crystals co-doped with Yb3+ ions absorb light near 975 nm 55 
and then efficiently emit visible light depending on the co-
dopant nature, Thus, the first step in optically characterizing 
up conversion nano cerias was to determine the Yb3+ absorp-
tion spectrum in cerium oxide nanoparticles host. Details of 
the experimental set up used for optical property measure- 60 
ment were previously described. 
FIG. 2a is a graph showing the optical absorption spectrum 
of up converter nano ceria and FIG. 2b shows the measured 
emission spectra of samples of (A) up converter nano ceria, 
(B) Ce02 :20Yb %, 2% Ho and (C) Ce02 :20% Yb, 0.5% Tm. 65 
The transition 4 F912 --;.
4 I512 lead to red emission in up con-
verter nano ceria with a small amount of green light (around 
present invention, the co-inventors chose several cell culture 
models includingA549 adenocarcinoma cells, WI-38 human 
lung fibroblasts and Human Umbilical Vein Endothelial 
cells-HUVECs. The toxicity by the metabolic reduction of 
a tetrazolium dye (MTT) or by the release oflactate dehydro-
genase (LDH) was assessed. By gauging cell viability using 
two independent methods, the co-inventors were confident 
that the cells are indeed viable under the experimental con-
ditions. 
When exposed to nanomolar and micromolar concentra-
tions of materials, no significant toxicity was observed in 
A549 or WI-38 cells as shown in the graphs shown in FIG. 4a 
and FIG. 4b, respectively. Some toxicity was observed in 
HUVECs in a dose dependent marmer when viability was 
determined by MTT assay, however no significant release of 
LDH occurred, suggesting the material caused a decrease in 
cellular metabolic rate without lysis of the cell membrane as 
shown in the graph of FIG. 4c. 
Toxicity results indicate that up conversion nano ceriums 
are not toxic in cell culture studies, a key finding for their 
potential use in biomedical applications. In order to visualize 
up conversion nano ceriums in a biological model, the above 
mentioned model cell types were exposed in cultured mono-
layers to varying doses of up conversion nano ceriums, and 
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observed a concentration-dependent increase in visible light 
emission when cells were excited using light at a wavelength 
of approximately 97 5 nm. An experimental set up was used to 
detect up conversion nano ceriums through the microscope. 
Particles were exposed to the culture models for 24 hours, 
cells were harvested by trypsin digest of extracellular matrix 
and then subsequently rep lated in culture dishes to form again 
a monolayer. Up converter nano cerias are absorbed by sev-
eral human cells in culture. 
10 
The kinetics of these reactions was determined by measur-
ing the decrease in absorbance of hydrogen peroxide at 
approximately 240 nm. In presence of 100 µM up conversion 
nano ceria, concentration of hydrogen peroxide reduced with 
time as shown in FIG. 6a. From this observation, it is evident 
that up conversion nano cerias are catalase mimetics, i.e. they 
convert hydrogen peroxide to molecular oxygen (02). 
Cells of A549 are shown in FIGS. Sa and Sb, HUVEC are 
shown in FIGS. Sc and Sd and WI-38 are shown in FIGS. Se 
and Sf, in the presence of ambient light in FIGS. la, Sc and Sf 
and near infrared excitation in FIGS. Sb, Sd and S/with a 
wavelength of approximately 975 nm, approximately 4 ns 
pulse rate, approximately 10 Hz pulse repeat rate and a pump 
power of approximately 170 mW. Cells were incubated with 
cell monolayers for 16 hours in the presence of 100 µM up 
converter nano ceria. Cells were subsequently removed by 
trypsination from the monolayer to exclude loosely bound 
and excess up converter nano cerias, washed extensively in 
phosphate buffer solution, and rep lated on glass cover slips in 
6-well tissue culture dishes. After 16 hours further incubation 
Although the mechanism of this activity is still under study, 
it could be due to radical scavenging properties of cerium 
10 oxide nanoparticles that have been recently reported by sev-
eral groups. In order to investigate the effect of up conversion 
ceria on cancer cell proliferation in vitro, cell viability of 
cancerous lung cells (CRL-5803) and normal lungs fibro-
15 blasts (CCL-135) were tested with various nanoparticle con-
centrations. Cell viability of both of the cells was measured 
72 hours post exposure to various concentrations of up con-
version nano ceria. In the case ofCRL-5803, proliferation of 
cancerous lung cells decreased by approximately 33.7% 
20 (p<0.0001) when exposed to approximately 100 nM of up . . 
convers10n nano cena. 
To determine if this decrease in cell proliferation and 
viability was due to an increase in the activation of apoptosis, 
caspase-3/7 activity was measured 72 hours post up conver-to allow for monolayer formation cells were fixed and 
observed by optical microscopy and the scale bar corresponds 
to 50 µm. 
The image captured by the CCD camera when the excita-
tion is on is shown in FIGS. Sb, Sd and Sf and the emitting 
nanoparticles can be seen as the red emitting items in the 
image. Arrows represent few of the particles which highlight 
under near infrared excitation. These images comprise only 
the replated cells, the results strongly suggest the up conver-
sion nano cerias are intracellular and not simply loosely 
bound material to cells. The particles are somewhat larger, 
suggesting that agglomeration is likely to take place inside the 
cells after absorption although cellular uptake of agglomer-
ated up conversion nano ceria is also possible. The aggrega-
tion of CNPs inside cells was shown in prior work by co-
inventors using TEM studies depending on the surface 
potential of cells and nanoparticles. 
25 sion nano ceria exposure. Caspase-3/7 activity increased by 
approximately 56.6% (p=0.012) when exposed to approxi-
mately 100 nM up conversion nano ceria. Under similar con-
ditions, proliferation of normal lung fibroblasts increased by 
approximately 21.5% (p=0.0178) when exposed to approxi-
30 mately 100 nM up conversion nano ceria. To determine if this 
increase in cell viability was due to a decrease in the activa-
tion of apoptosis, caspase-3/7 activity was measured approxi-
mately 72 hours after up conversion nano ceria exposure. 
Caspase-3/7 activity did not significantly change in normal 
35 lung fibroblasts that were exposed to the various concentra-
tions of up conversion nano ceria. 
Recently co-inventors reported that under in vitro condi-
tions, the cellular uptake of nanoparticles differs between a 
normal versus a tumor cell and can be attributed to the differ-
40 ence in intercellular activity, as well as cell structure. As a 
result of regenerative antioxidant properties of up conversion 
nano ceria, nanoparticles may reduce the proliferation of 
cancer cells. Nonetheless, recent studies on ZnO and Ti02 
Cellular uptake of smaller as well as larger (agglomerates) 
particles have also been reported. Transport of small particles 
primarily occurs by diffusion and endocytosis, while uptake 
oflargerparticles could be facilitated by sedimentation on the 
culture monolayer. Although the current optics used to image 45 
this particles have shown mostly agglomerated particles, still 
there may be the presence of finer particles which may be too 
weak to be observed with nanometer resolution using the 
experimental capabilities. 
Co-inventors have previously shown that cerium oxide 50 
nanoparticles can scavenge free radicals and mimic enzy-
matic antioxidants such as superoxide dismutase and cata-
lase. Since up conversion nano cerias are biocompatible, bio-
logical catalytic activity was tested for potential biomedical 
applications. Catalse mimetic activity of up conversion nano 55 
cerias were followed by monitoring the peroxide levels using 
ultraviolet-visible spectrophotometry. FIG. 6a illustrates the 
role of up converter nano cerias in catalase mimetic activity 
and cancer treatment. FIG. 6a shows the conversion of hydro-
gen peroxide to oxygen was followed by measuring decreases 60 
in hydrogen peroxide levels via ultraviolet absorption ( absor-
bance maximum at 240 nm). A representative experiment 
with at least three independent samples is shown, and the 
experiment was repeated at least two times on two prepara-
tions of cerium oxide nanoparticles. Data plotted represent 65 
the mean of at least three samples and the error plotted is the 
standard deviation of the mean. 
show that these nanoparticles exert cancer killing activity 
through the reactive oxygen species generation or surface 
interaction with cells. 
Recently, it has been reported that europium hydroxide 
nanorods show pro-angiogenic properties due to the forma-
tion of reactive oxygen species in a concentration dependent 
manner. 
Based on the above facts, it is expected that up conversion 
nano cerias affect the equilibrium oxygen concentration of 
the cells in a cell specific reaction. In the case of cancerous 
cells it probably generates reactive oxygen species which 
annihilates the cancerous cells while enhancing the normal 
cell proliferation. 
In conclusion, for biomedical application of up conversion 
nanoparticles, studies on toxicity are of considerable impor-
tance to understand the properties and potential applications. 
In this study conducted for the present invention, co-doped 
cerium oxide nanoparticles were synthesized by precipitation 
technique. Up conversion nano cerias that are biocompatible 
have shown to be a potential biomarker with antioxidant 
properties. Up conversion nano cerias interact in a cell spe-
cific manner preventing cancer cell proliferation while pro-
tecting normal cells, which can have a far reaching impact in 
future cancer research. With suitable surface targeting 
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ligands, up conversion nano cerias could be used for site 
selective drug delivery for the treatment of diseases like can-
cer. 
In summary, a first embodiment provides a method of 
doping a cerium oxide nanoparticle with one or more dopants 
12 
conversion nanoceria emitters that absorb infrared light 
and emit a red, a green or a blue light through the process 
of up conversion. 
2. A biocompatible non toxic up conversion nanoparticle 
consisting essentially of: 
a cerium oxide nanoparticle doped with Yb3 + as a sensitizer 
and Ho3+ as an emitter to form up conversion nano ceria 
that absorbs infrared light and emits visible light through 
the process of up conversion to emit red light as a bio-
compatible non toxic nano rare earth up conversion for 
imaging and therapeutics. 
3. An up conversion nanoparticle consisting essentially of 
a doped nano ceria based up conversion material consisting 
essentially of: 
a ceria base material; 
a Yb sensitizer dopant ion doped into the ceria base mate-
rial; and 
at least one emitter dopant ion selected from the group 
consisting of Ho, Tm and Pr emitter dopant ions, also 
doped into the ceria base material. 
to form co-doped up conversion nanoparticle ceria, at least 
one of the dopants absorbing infrared light and emitting vis-
ible light through the process of up conversion. The dopants 
are one or more nitrates selected from the group including of 
Yb, Er, Ho, Tm and Pr, such as co-doping Yb with one or more 10 
nitrates from the group consisting of Er, Ho, Tm and Pr, 
doping a cerium oxide nanoparticle with one of Yb3+ and 
Er3+, or adding one of Er3+, Ho3 + and Tm3 + to the Ce02 
nanoparticle. in an embodiment the up conversion nanopar-
ticle ceria are Er, Yb doped Ce02 particles. Applications 15 
include using the up converting nano ceria nanoparticles to 
locate cells using the up converting nano ceria nanoparticles 
for finding, tracking and evaluating therapeutic agents in 
biological systems. The cerium oxide nanoparticle can be 
co-doped with an up-converting material to form an up con- 20 
version nano ceria that absorbs infrared light and emits visible 
light through the process of up conversion including emitting 
one of a red, a green and a blue light. 
4. The nanoparticle of claim 3 wherein the doped nano 
ceria based up conversion material absorbs in the infrared 
wavelength range and emits in the visible wavelength range. 
5. The nanoparticle of claim 4 wherein the nano ceria based 
up conversion material emits in the red portion of the visible 
25 wavelength range. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope of 
the invention is not intended to be, nor should it be deemed to 
be, limited thereby and such other modifications or embodi-
ments as may be suggested by the teachings herein are par-
ticularly reserved especially as they fall within the breadth 
and scope of the claims here appended. 
We claim: 
1. An up conversion nano ceria for site selective drug 
delivery and treatment of disease consisting essentially of: 
a water dispersible non toxic up conversion nano ceria 
consisting essentially of: 
a cerium oxide nanoparticle doped with Yb ions and at least 
one of an upconverting Ho, Tm, and Pr ion to form up 
6. The nanoparticle of claim 4 wherein the nano ceria based 
up conversion material emits in the green portion of the vis-
ible wavelength range. 
7. The nanoparticle of claim 4 wherein the nano ceria based 
30 up conversion material emits in the blue portion of the visible 
wavelength range. 
35 
8. An up conversion nanoparticle selected from the group 
consisting ofCe02:20% Yb, 2% Ho and Ce02:20% Yb, 0.5% 
Tm. 
9. The up conversion nanoparticle of claim 3 wherein a size 
of the nanoparticle is from about 7 to about 10 nanometers. 
10. The up conversion nanoparticle of claim 3 wherein a 
latticeparameterofthenanoparticleis from 0.5412 to 0.5423. 
* * * * * 
